Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 02, 2015 12:30 AM ET


Company Overview of Capricor Therapeutics, Inc.

Company Overview

Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.

8840 Wilshire Boulevard

2nd Floor

Beverly Hills, CA 90211

United States

Founded in 2005

28 Employees



Key Executives for Capricor Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and Secretary
Age: 61
Total Annual Compensation: $243.8K
Vice President of Medical Affairs
Age: 52
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

Capricor Therapeutics, Inc. Key Developments

Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

Capricor Therapeutics, Inc. announced that it has completed enrollment of its first Phase II clinical trial of Cenderitide in ambulatory heart failure patients. Cenderitide is in development for the outpatient treatment of patients following an acute admission for heart failure, as well as other potential indications. The trial completed enrollment of 14 patients. Patients received up to eight consecutive days of increasing doses of Cenderitide by continuous subcutaneous infusion using Insulet's OmniPod® drug delivery system. The trial assessed the safety, tolerability, pharmacokinetic profile and pharmacodynamic response to increasing dose levels of open-label Cenderitide administered in a stepwise fashion, with each patient receiving the entire range of doses.

Capricor Therapeutics, Inc. Announces Earnings Results for the Fiscal Year Ended December 31, 2014

Capricor Therapeutics, Inc. announced earnings results for the fiscal year ended December 31, 2014. The company reported net loss of $6.2 million or $0.53 per basic and diluted share.

Capricor Therapeutics, Inc., Q4 2014 Earnings Call, Mar 18, 2015

Capricor Therapeutics, Inc., Q4 2014 Earnings Call, Mar 18, 2015

Similar Private Companies By Industry

Company Name Region
AMBA Biosciences, LLC United States
POINT Biomedical Corp. United States
Rinat Neuroscience Corporation United States
BioAgra, LLC United States
Exiqon Diagnostics, Inc. United States

Recent Private Companies Transactions

Private Placement
February 3, 2015
Private Placement
January 9, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Capricor Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at